Literature DB >> 19846408

Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis.

Karim Raza, Linda Mathsson, Christopher D Buckley, Andrew Filer, Johan Rönnelid.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19846408     DOI： 10.1136/ard.2009.118448

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.

Authors:  Z Reyes-Castillo; C A Palafox-Sánchez; I Parra-Rojas; G E Martínez-Bonilla; S del Toro-Arreola; M G Ramírez-Dueñas; G Ocampo-Bermudes; José F Muñoz-Valle
Journal:  Clin Exp Immunol       Date:  2015-09-16       Impact factor: 4.330

2.  Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin.

Authors:  Ulrike Harre; Dan Georgess; Holger Bang; Aline Bozec; Roland Axmann; Elena Ossipova; Per-Johan Jakobsson; Wolfgang Baum; Falk Nimmerjahn; Eszter Szarka; Gabriella Sarmay; Grit Krumbholz; Elena Neumann; Rene Toes; Hans-Ulrich Scherer; Anca Irinel Catrina; Lars Klareskog; Pierre Jurdic; Georg Schett
Journal:  J Clin Invest       Date:  2012-04-16       Impact factor: 14.808

3.  Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.

Authors:  Georgia Barouta; Christina G Katsiari; Ioannis Alexiou; Christos Liaskos; Areti Varna; Dimitrios P Bogdanos; Anastasios E Germenis; Lazaros I Sakkas
Journal:  Clin Rheumatol       Date:  2016-12-10       Impact factor: 2.980

4.  Unique correlation between mutated citrullinated vimentine IgG autoantibodies and markers of systemic inflammation in rheumatoid arthritis patients.

Authors:  Walid E Zahran; Magda I Mahmoud; Kamal A Shalaby; Manal H Abbas
Journal:  Indian J Clin Biochem       Date:  2012-10-17

Review 5.  The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis.

Authors:  Katleen Van Steendam; Kelly Tilleman; Dieter Deforce
Journal:  Rheumatology (Oxford)       Date:  2011-01-27       Impact factor: 7.580

6.  Comparison of two assays to determine anti-citrullinated peptide antibodies in rheumatoid arthritis in relation to other chronic inflammatory rheumatic diseases: assaying anti-modified citrullinated vimentin antibodies adds value to second-generation anti-citrullinated cyclic peptides testing.

Authors:  Miriam Lizette Díaz-Toscano; Eva Maria Olivas-Flores; Soraya Amali Zavaleta-Muñiz; Jorge Ivan Gamez-Nava; Ernesto German Cardona-Muñoz; Manuel Ponce-Guarneros; Uriel Castro-Contreras; Arnulfo Nava; Mario Salazar-Paramo; Alfredo Celis; Nicte Selene Fajardo-Robledo; Esther Guadalupe Corona-Sanchez; Laura Gonzalez-Lopez
Journal:  Biomed Res Int       Date:  2014-06-15       Impact factor: 3.411

Review 7.  Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Authors:  Vasco Crispim Romão; Helena Canhão; João Eurico Fonseca
Journal:  BMC Med       Date:  2013-01-23       Impact factor: 8.775

8.  Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families.

Authors:  Seong-Kyu Kim; Jisuk Bae; Hwajeong Lee; Ji Hun Kim; Sung-Hoon Park; Jung-Yoon Choe
Journal:  Korean J Intern Med       Date:  2012-12-28       Impact factor: 2.884
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.